Pharmaceutical company developing a synthetic version of psilocybin (found in magic mushrooms) for treatment-resistant depression. Its drug has completed key late-stage trials. Compass is the firm closest to filing an application for FDA approval of a psychedelic medicine.
On April 18th 2026 Donald Trump signed an executive order boosting psychedelic medicines, including new research funding and priority vouchers to speed FDA review. The company said it aimed to submit its final data to the FDA in the third quarter of 2026.
Forgetfulness, n.: A gift of God bestowed upon debtors in compensation for their destitution of conscience.